Laterality in functional brain imaging studies of schizophrenia

Schizophrenia Bulletin

Volumn 25, Issue 1, 1999, Pages 141-156

  Gur, Raquel E ^a,b   Chin, Samuel ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Functional brain imaging; Hemispheric activity; Laterality

Indexed keywords

BRAIN RECEPTOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; GLUCOSE; NEUROLEPTIC AGENT; RACLOPRIDE; SEROTONIN 2A RECEPTOR; XENON 133;

ARTICLE; BRAIN BLOOD FLOW; BRAIN FUNCTION; CEREBROSPINAL FLUID; GLUCOSE METABOLISM; HEMISPHERIC DOMINANCE; HUMAN; LEFT HEMISPHERE; NEUROPHARMACOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0033004836     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033361     Document Type: Article

References (87)

1. Anderson, J; Fawdry, R.; Gordon, E.; Coyle, S.; Gruenewald, S.; and Meares, R.A. SPECT asymmetry of left temporal lobe in hallucinated schizophrenics. [Abstract] Biological Psychiatry, 29:291, 1991.
2. Andreasen, N.C.; O'Leary, D.S.; Flaum, M.; Nopoulos, P.; Watkins, G.L.; Boles Ponto, L.L.; and Hichwa, R.D. Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients. Lancet, 349:1730-1734, 1997.
3. Andreasen, N.C.; Rezai, K.; Alliger, R.; Swayze, V.W., II; Flaum, M.; Kirchner, P.; Cohen, G.; and O'Leary, D.S. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: Assessment with Xenon 133 single-photon emission computed tomography and the tower of London. Archives of General Psychiatry, 49:943-958, 1992.
4. Bandettini, P.A.; Wong, E.C.; Hinks, R.S.; Tikofsky, R.S.; and Hyde, J.S. Time course of EPI of human brain function during task activation. Magnetic Resonance in Medicine, 25:390-397, 1992.
5. Bertollo, D.N.; Cowen, M.A.; and Levy, A.V. Hypometabolism in olfactory cortical projection areas of male patients with schizophrenia: An initial positron emission tomography study. Psychiatry Research, 60:113-116, 1996.
6. Biver, F.; Goldman, S.; Luxen, A.; Delvenne, V.; De Maertelaer, V.; De La Fuente, J.; Mendlewicz, J.; and Lotstra, F. Altered frontostriatal relationship in unmedicated schizophrenic patients. Psychiatry Research, 61:161-171, 1995.
7. Breier, A.; Su, T.P.; Saunders, R.; Carson, R.E.; Kolachana, B.S.; de Bartolomeis, A.; Weinberger, D.R.; Weisenfeld, N.; Malhotra, A.K.; Eckelman, W.C.; and Pickar, D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America, 94:2569-2574, 1997.
8. Buchsbaum, M.S. The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophrenia Bulletin, 16(3):377-387, 1990.
9. Buchsbaum, M.S.; Ingvar, D.H.; Kessler, R.; Water, R.N.; Cappeletti, J.; Van Kammen, D.P.; King, A.C.; Johnson, J.L.; Manning, R.G.; Flynn, R.N.; Mann, L.S.; Bunney, W.E.; and Sokoloff, L. Cerebral glucography with positron tomography. Archives of General Psychiatry, 39:251-259, 1987.
10. Buchsbaum, M.S.; Potkin, S.G.; Siegel, B.V., Jr.; Lohr, J.; Katz, M.; Gottschalk, L.A.; Gulasekaram, B.; Marshall, J.F.; Lottenberg, S.; Teng, C.Y.; Abel, L.; Plon, L.; and Bunney, W.E., Jr. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Archives of General Psychiatry, 49:966-974, 1992.
11. Buchsbaum, M.S.; Someya, T.; Teng, C.Y.; Abel, L.; Chin, S.; Najafi, A.; Haier, R.J.; Wu, J.; and Bunney, W.E., Jr. PET and MRI of the thalamus in never-medicated patients with schizophrenia. American Journal of Psychiatry, 153:191-199, 1996.
12. Burnet, P.W.; Eastwood, S.L.; and Harrison, P.J. [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: A comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochemistry International, 30:565-574, 1997.
13. Carlsson, M., and Carlsson, A. Interactions between glutaminergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. Trends in Neurosciences, 13:272-276, 1990.
14. Cleghorn, J.M. Regional brain metabolism during auditory hallucinations in chronic schizophrenia. British Journal of Psychiatry, 157:562-570, 1990.
15. Cohen, R.M.; Nordahl, T.E.; Semple, W.E.; Andreason, P.; Litman, R.E.; and Pickar, D. The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. Archives of General Psychiatry, 54:481-486, 1997.
16. Cowell, P.E.; Fitch, R.H.; and Denenberg, V.H. Laterality in animals: Relevance to schizophrenia. Schizophrenia Bulletin, 25(1):41-62, 1999.
17. 99mTc-HMPAO SPECT study. Psychological Medicine, 26(2):265-277, 1996.
18. Crow, T.J. Temporal lobe asymmetries as the key to the etiology of schizophrenia. Schizophrenia Bulletin, 16(3):433-443, 1990.
19. Dao-Castellana, M.H.; Paillere-Martinot, M.L.; Hantraye, P.; Attar-Levy, D.; Remy, P.; Crouzel, C.; Artiges, E.; Feline, A.; Syrota, A.; and Martinot, J.L. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Research, 23:167-174, 1997.
20. Dean, B., and Hayes, W. Decreased frontal cortical serotonin 2A receptors in schizophrenia. Schizophrenia Research, 21:133-139, 1996.
21. Dean, B.; Pavey, G.; and Opeskin, K. [3H]Raclopride binding to brain tissue from subjects with schizophrenia: Methodological aspects. Neuropharmacology, 36:779-786, 1997.
22. DeLisi, L.E.; Buchsbaum, M.S.; Holcomb, H.H.; Langston, K.C.; King, A.C.; Kessler, R.; Pickar, D.; Carpenter, W.T., Jr.; Morihisa, J.M.; Margolin, R.; and Weinberger, D.R. Increased temporal lobe glucose use in chronic schizophrenic patients. Biological Psychiatry, 25:835-851, 1989.
23. Early, T.S.; Reiman, E.M.; Raichle, M.E.; and Spitznagel, E.L. Left globus pallidus abnormality in never-medicated patients with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 84:561-563, 1989.
24. 11C]raclopride. Psychopharmacology, 107:23-29, 1992.
25. Farde, L.; Wiesel, F.A.; Halldin, C.; and Sedvall, G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry, 45:71-76, 1988.
26. Farde, L.; Wiesel, F.A.; Stone-Elander, S.; Halldin, C.; Nordstrom, A.L.; Hall, H.; and Sedvall, G. D2 dopamine receptors in neuroleptic-naive schizophrenic patients: A positron emission tomography study with 11C raclopride. Archives of General Psychiatry, 47:213-221, 1990.
27. Fletcher, P.C.; Frith, C.D.; Grasby, P.M.; Friston, K.J.; and Dolan, R.J. Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. Journal of Neuroscience, 16:7055-7062, 1996.
28. Flor-Henry, P. Lateralized temporal-limbic dysfunction and psychopathology. Annals of the New York Academy of Sciences, 280:777-795, 1976.
29. Friston, K.J.; Frith, C.D.; Fletcher, P.; Liddle, P.F.; and Frackowiak, R.S. Functional topography: Multidimensional scaling and functional connectivity in the brain. Cerebral Cortex, 6:156-164, 1996.
30. Ganguli, R.; Carter, C.; Mintun, M.; Brar, J.; Becker, J.; Sarma, R.; Nichols, T.; and Bennington, E. PET brain mapping study of auditory verbal supraspan memory versus visual fixation in schizophrenia. Biological Psychiatry, 41:33-42, 1997.
31. Goldsmith, S.K.; Shapiro, R.M.; and Joyce, J.N. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia: A postmortem study. Archives of General Psychiatry, 54:649-658, 1997.
32. Goyer, P.F.; Berridge, M.S.; Morris, E.D.; Semple, W.E.; Compton-Toth, B.A.; Schulz, S.C.; Wong, D.F.; Miraldi, F.; and Meltzer, H.Y. PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. Journal of Nuclear Medicine, 37:1122-1127, 1996.
33. Gur, R.C.; Erwin, R.J.; and Gur, R.E. Neurobehavioral probes for physiologic neuroimaging studies. Archives of General Psychiatry, 49:409-414, 1992.
34. Gur, R.E. Functional brain imaging studies in schizophrenia. In: Bloom, F.E., and Kupfer, D.J., eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, 1995. pp. 1185-1192.
35. Gur, R.E.; Mozley, P.D.; Resnick, S.M.; Mozley, L.H.; Shtasel, D.L.; Gallacher, F.; Arnold, S.E.; Karp, J.S.; Alavi, A.; Reivich, M.; and Gur, R.C. Resting cerebral glucose metabolism and clinical features of schizophrenia. Archives of General Psychiatry, 52:657-667, 1995.
36. Gur, R.E., and Pearlson, G.D. Neuroimaging in schizophrenia research. Schizophrenia Bulletin, 19(2):337-353, 1993.
37. Gur, R.E.; Resnick, S.M.; Alavi, A.; Gur, R.C.; Caroff, S.; Dann, R.; Silver, F.L.; Saykin, A.J.; Chawluk, J.B.; Kushner, M.; and Reivich, M. Regional brain function in schizophrenia: I. A positron emission tomography study. Archives of General Psychiatry, 44:119-125, 1987a.
38. Gur, R.E.; Resnick, S.M.; and Gur, R.C. Laterality and frontality of cerebral blood flow and metabolism in schizophrenia: Relationship to symptom specificity. Psychiatry Research, 27:325-334, 1989.
39. Gur, R.E.; Resnick, S.M.; Gur, R.C.; Alavi, A.; Caroff, S.; Kushner, M.; and Reivich, M. Regional brain function in schizophrenia: II. Repeated evaluation with positron emission tomography. Archives of General Psychiatry, 44:126-129, 1987b.
40. Helmeste, D.M.; Tang, S.W.; Bunney, W.E., Jr.; Potkin, S.G.; and Jones, E.G. Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains. European Journal of Pharmacology, 314:R3-5, 1996.
41. Holcomb, H.H.; Cascella, N.G.; Thaker, G.K.; Medoff, D.R.; Dannals, R.F.; and Tamminga, C.A. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. American Journal of Psychiatry, 153:41-49, 1996.
42. Kapur, S.; Remington, G.; Jones, C.; Wilson, A.; DaSilva, J.; Houle, S.; and Zipursky, R. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: A PET study. American Journal of Psychiatry, 153:948-950, 1996.
43. Kapur, S.; Zipursky, R.; Roy, P.; Jones, C.; Remington, G.; Reed, K.; and Houle, S. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: A PET study. Psychopharmacology, 131:148-152, 1997.
44. Katz, M.; Buchsbaum, M.S.; Siegel, B.V., Jr.; Wu, J.; Haier, R.J.; and Bunney, W.E., Jr. Correlational patterns of cerebral glucose metabolism in never-medicated schizophrenics. Neuropsychobiology, 33:1-11, 1996.
45. Kawasaki, Y.; Maeda, Y.; Sakai, N.; Higashima, M.; Yamaguchi, N.; Koshino, Y.; Hisada, K.; Suzuki, M.; and Matsuda, H. Regional cerebral blood flow in patients with schizophrenia: Relevance to symptom structures. Psychiatry Research, 67:49-58, 1996.
46. Klemm, E.; Danos, P.; Grunwald, F.; Kasper, S.; Moller, H.J.; and Biersack, H.J. Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression - A study with single photon emission computed tomography. Psychiatry Research, 68:1-10, 1996a.
47. Klemm, E.; Grunwald, F.; Kasper, S.; Menzel, C.; Broich, K.; Danos, P.; Reichmann, K.; Krappel, C.; Rieker, O.; Briele, B.; Hotze, A.L.; Moller, H.J.; and Biersack, H.J. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. American Journal of Psychiatry, 153:183-190, 1996b.
48. Knable, M.B.; Hyde, T.M.; Murray, A.M.; Herman, M.M.; and Kleinman, J.E. A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls. Biological Psychiatry, 40:1191-1199, 1996.
49. Kotrla, K.J., and Weinberger, D.R. Brain imaging in schizophrenia. Annual Review of Medicine, 46:113-122, 1995.
50. Kufferle, B.; Brucke, T.; Topitz-Schratzberger, A.; Tauscher, J.; Gossler, R.; Vesely, C.; Asenbaum, P.; Podreka, I.; and Kasper, S. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Psychiatry Research, 68:23-30, 1996.
51. Kwong, K.; Belliveau, J.W.; Chesler, D.A.; Goldberg, I.E.; Weisskoff, R.M.; Poncelet, B.P.; Kennedy, D.N.; Hoppel, B.E.; Cohen, M.S.; Turner, R.; Cheng, H.M.; Brady, T.J.; and Rosen, B.R. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proceedings of the National Academy of Sciences of the United States of America, 89:5675-5679, 1992.
52. Lahti, R.A.; Roberts, R.C.; Conley, R.R.; Cochrane, E.V.; Mutin, A.; and Tamminga, C.A. D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. Neuroreport, 7:1945-1948, 1996.
53. Laruelle, M.; Abi-Dargham, A.; van Dyck, C.H.; Gil, R.; D'Souza, C.D.; Erdos, J.; McCance, E.; Rosenblatt, W.; Fingado, C.; Zoghbi, S.S.; Baldwin, R.M.; Seibyl, J.P.; Krystal, J.H.; Charney, D.S.; and Innis, R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America, 93:9235-9240, 1996.
54. Liddle, P.F.; Friston, K.J.; Frith, C.D.; Hirsch, S.R.; Jones, T.; and Frackowiak, R.S.J. Patterns of cerebral blood flow in schizophrenia. British Journal of Psychiatry, 160:179-186, 1992.
55. Miller, D.D.; Rezai, K.; Alliger, R.; and Andreasen, N.C. The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: Assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography. Biological Psychiatry, 41:550-559, 1997.
56. Mozley, L.H.; Gur, R.C.; Gur, R.E.; Mozley, P.D.; and Alavi, A. The relationship between verbal memory performance and the cerebral distribution of FDG in patients with schizophrenia. Biological Psychiatry, 40:443-451, 1996.
57. Musalek, M.; Podreka, I.; Walter, S.; Suess, E.; Passweg, V.; Nutzinger, D.; Strobl, R.; and Lesch, O.M. Regional brain function in hallucinations: A study of regional cerebral blood flow with 99m-Tc-HMPAO-SPECT in patients with auditory hallucinations, tactile hallucinations, and normal controls. Comprehensive Psychiatry, 30:99-108, 1989.
58. Nyberg, S.; Farde, L.; and Halldin, C. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy: A PET study in haloperidol-treated patients. Psychiatry Research, 67:163-171, 1996.
59. O'Leary, D.S.; Andreasen, N.C.; Hurtig, R.R.; Kesler, M.L.; Rogers, M.; Arndt, S.; Cizadlo, T.; Watkins, G.L.; Ponto, L.L.; Kirchner, P.T.; and Hichwa, R.D. Auditory attentional deficits in patients with schizophrenia: A positron emission tomography study. Archives of General Psychiatry, 53(7):633-641, 1996.
60. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale. Psychological Reports, 10:799-812, 1962.
61. Petty, R. Structural asymmetries of the human brain and their disturbance in schizophrenia. Schizophrenia Bulletin, 25(1):121-139, 1999.
62. Pickar, D.; Su, T.P.; Weinberger, D.R.; Coppola, R.; Malhotra, A.K.; Knable, M.B.; Lee, K.S.; Gorey, J.; Bartko, J.J.; Breier, A.; and Hsiao, J. Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients. American Journal of Psychiatry, 153:1571-1578, 1996.
63. Pilowsky, L.S.; Busatto, G.F.; Taylor, M.; Costa, D.C.; Sharma, T.; Sigmundsson, T.; Ell, P.J.; Nohria, V.; and Kerwin, R.W. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - A 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology, 124:148-153, 1996.
64. Renshaw, P.F.; Yurgelun-Todd, D.A.; and Cohen, B.M. Greater hemodynamic response to photic stimulation in schizophrenic patients: An echo planar MRI study. American Journal of Psychiatry, 151:1493-1495, 1994.
65. Resnick, S.M.; Gur, R.E.; Alavi, A.; Gur, R.C.; and Reivich, M. Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatry Research, 24:1-11, 1988.
66. Rubin, P.; Holm, S.; Friberg, L.; Vodebech, P.; Andersen, H.S.; Bendsen, B.B.; Stromso, N.; Larsen, J.K.; Lassen, N.A.; and Hemmingsen, R. Altered modulation of prefrontal and subcortical brain activity in newly diagnosed schizophrenia and schizophreniform disorder: A regional cerebral blood flow study. Archives of General Psychiatry, 48:987-995, 1991.
67. Sabri, O.; Erkwoh, R.; Schreckenberger, M.; Cremerius, U.; Schulz, G.; Dickmann, C.; Kaiser, H.J.; Steinmeyer, E.M.; Sass, H.; and Buell, U. Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. Journal of Nuclear Medicine, 38:181-188, 1997.
68. Saykin, A.J.; Gur, R.C.; Gur, R.E.; Mozley, D.; Mozley, L.H.; Resnick, S.M.; Kester, D.B.; and Stafiniak, P. Neuropsychological function in schizophrenia: Selective impairment in memory and learning. Archives of General Psychiatry, 48:618-624, 1991.
69. Schneider, K. Clinical Psychopathology. Translated by M.W. Hamilton. New York, NY: Grune & Stratton, 1959.
70. Schroder, J.; Bubeck, B.; Demisch, S.; and Sauer, H. Benzodiazepine receptor distribution and diazepam binding in schizophrenia: An exploratory study. Psychiatry Research, 68:125-131, 1997.
71. Schroder, J.; Buchsbaum, M.S.; Siegel, B.V.; Geider, F.J.; Lohr, J.; Tang, C.; Wu, J.; and Potkin, S.G. Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schizophrenia Research, 19:41-53, 1996.
72. Sedvall, G.C. The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology, 7:41-54, 1992.
73. Sedvall, G.; Farde, L.; Persson, A.; and Weisel, F.A. Imaging of neurotransmitter receptors in the living human brain. Archives of General Psychiatry, 3:995-1005, 1986.
74. Seeman, P.; Guan, H.C.; Nobrega, J.; Jiwa, D.; Markstein, R.; Balk, J.H.; Picetti, R.; Borrelli, E.; and Van Tol, H.H. Dopamine D2-like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline. Synapse, 25:137-146, 1997.
75. Sheppard, G.; Gruzelier, J.; Manchanda, R.; Hirsch, S.R.; Wise, R.; Frackowiak, R.; and Jones, T. 15-O positron emission tomographic scanning in predominantly never-treated acute schizophrenic patients. Lancet, II:1448-1452, 1983.
76. Siegel, B.V.; Buchsbaum, M.S.; Bunney, W.E., Jr.; Gottschalk, L.A.; Haier, R.J.; Lohr, J.B.; Lottenberg, S.; Najafi, A.; Nuechterlein, K.H.; Potkin, S.G.; and Wu, J.C. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. American Journal of Psychiatry, 150:1325-1336, 1993.
77. Simpson, M.D.; Lubman, D.I.; Slater, P.; and Deakin, J.F. Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal, cortex in schizophrenia. Biological Psychiatry, 39:919-928, 1996.
78. Steinberg, J.L.; Devous, M.D., Sr.; and Paulman, R.G. Wisconsin card sorting activated regional cerebral blood flow in first break and chronic schizophrenic patients and normal controls. Schizophrenia Research, 19:177-187, 1996.
79. Tamminga, C.A.; Thaker, G.K.; Buchanan, R.; Kirkpatrick, B.; Alphs, L.D.; Chase, T.N.; and Carpenter, W.T., Jr. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Archives of General Psychiatry, 49:522-530, 1992.
80. Vita, A.; Bressi, S.; Perani, D.; Invernizzi, G.; Giobbio, G.M.; Dieci, M.; Garbarini, M.; Del Sole, A.; and Fazio, F. High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. American Journal of Psychiatry, 152:876-882, 1995.
81. Weinberger, D.R.; Berman, K.F.; and Zec, R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow evidence. Archives of General Psychiatry, 43:114-125, 1986.
82. Wenz, F.; Schad, L.R.; Knopp, M.V.; Baudendistel, K.T.; Flomer, F.; Schroder, J.; and Van Kaick, G. Functional magnetic resonance imaging at 1.5 T: Activation pattern in schizophrenic patients receiving neuroleptic medication. Magnetic Resonance Imaging, 12:975-982, 1994.
83. Wolkin, A.; Angrist, B.; Wolf, A.; Brodie, J.D.; Wolkin, B.; Jaeger, J.; Cancro, R.; and Rotrosen, J. Low frontal glucose utilization in chronic schizophrenia: A replication study. American Journal of Psychiatry, 145:251-253, 1988.
84. Wolkin, A.; Sanfilipo, M.; Duncan, E.; Angrist, B.; Wolf, A.P.; Cooper, T.B.; Brodie, J.D.; Laska, E.; and Rotrosen, J.P. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms. American Journal of Psychiatry, 153:346-354, 1996.
85. Wong, D.F.; Pearlson, G.D.; Tune, L.E.; Young, L.T.; Meltzer, C.C.; Dannals, R.F.; Ravert, H.T.; Reith, J.; Kuhar, M.J.; and Gjedde, A. Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. Journal of Cerebral Blood Flow and Metabolism, 17:331-342, 1997.
86. Wong, D.F.; Wagner, H.N.; Tune, L.E.; Dannals, R.F.; Pearlson, G.D.; Links, J.M.; Tamminga, C.A.; Broussolle, E.P.; Ravert, H.T.; Wilson, A.A.; Toung, J.K.T.; Malat, J.; Williams, F.A.; O'Touma, L.A.; Snyder, S.H.; Kuhar, M.J.; and Gjedde, A. Positron emission tomography reveals elevated D2 receptors in drug-naive schizophrenics. Science, 234:1558-1563, 1986.
87. Yurgelun-Todd, D.A.; Waternaux, C.M.; Cohen, B.M.; Gurber, S.A.; English, C.D.; and Renshaw, P.F. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. American Journal of Psychiatry, 153:200-205, 1996.